385 related articles for article (PubMed ID: 25991433)
1. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).
Gehringer M; Muth F; Koch P; Laufer SA
Expert Opin Ther Pat; 2015; 25(8):849-72. PubMed ID: 25991433
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents.
Messoussi A; Feneyrolles C; Bros A; Deroide A; Daydé-Cazals B; Chevé G; Van Hijfte N; Fauvel B; Bougrin K; Yasri A
Chem Biol; 2014 Nov; 21(11):1433-43. PubMed ID: 25442375
[TBL] [Abstract][Full Text] [Related]
3. A patent review of MAPK inhibitors (2018 - present).
Wydra VR; Ditzinger RB; Seidler NJ; Hacker FW; Laufer SA
Expert Opin Ther Pat; 2023; 33(6):421-444. PubMed ID: 37501497
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of c-Jun N-terminal kinases: an update.
Koch P; Gehringer M; Laufer SA
J Med Chem; 2015 Jan; 58(1):72-95. PubMed ID: 25415535
[TBL] [Abstract][Full Text] [Related]
5. Designed ankyrin repeat proteins (DARPins) as novel isoform-specific intracellular inhibitors of c-Jun N-terminal kinases.
Parizek P; Kummer L; Rube P; Prinz A; Herberg FW; Plückthun A
ACS Chem Biol; 2012 Aug; 7(8):1356-66. PubMed ID: 22568706
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances in c-Jun N-Terminal Kinase (JNK) Inhibitors.
Li G; Qi W; Li X; Zhao J; Luo M; Chen J
Curr Med Chem; 2021; 28(3):607-627. PubMed ID: 32039671
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the Design and Discovery of c-Jun N-Terminal Kinase Inhibitors and Their Therapeutic Potential in Human Diseases.
Zhu Y; Shuai W; Zhao M; Pan X; Pei J; Wu Y; Bu F; Wang A; Ouyang L; Wang G
J Med Chem; 2022 Mar; 65(5):3758-3775. PubMed ID: 35200035
[TBL] [Abstract][Full Text] [Related]
9. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential.
Bogoyevitch MA; Boehm I; Oakley A; Ketterman AJ; Barr RK
Biochim Biophys Acta; 2004 Mar; 1697(1-2):89-101. PubMed ID: 15023353
[TBL] [Abstract][Full Text] [Related]
10. c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia.
Waetzig V; Czeloth K; Hidding U; Mielke K; Kanzow M; Brecht S; Goetz M; Lucius R; Herdegen T; Hanisch UK
Glia; 2005 May; 50(3):235-46. PubMed ID: 15739188
[TBL] [Abstract][Full Text] [Related]
11. The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): differences revealed by gene targeting.
Bogoyevitch MA
Bioessays; 2006 Sep; 28(9):923-34. PubMed ID: 16937364
[TBL] [Abstract][Full Text] [Related]
12. JNK inhibitors as anti-inflammatory and neuroprotective agents.
Graczyk PP
Future Med Chem; 2013 Apr; 5(5):539-51. PubMed ID: 23573972
[TBL] [Abstract][Full Text] [Related]
13. Dual leucine zipper kinase (MAP3K12) modulators: a patent review (2010-2015).
Oetjen E; Lemcke T
Expert Opin Ther Pat; 2016 May; 26(5):607-16. PubMed ID: 27043251
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic promise of JNK ATP-noncompetitive inhibitors.
Bogoyevitch MA
Trends Mol Med; 2005 May; 11(5):232-9. PubMed ID: 15882611
[TBL] [Abstract][Full Text] [Related]
15. Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1.
Lu W; Liu Y; Gao Y; Geng Q; Gurbani D; Li L; Ficarro SB; Meyer CJ; Sinha D; You I; Tse J; He Z; Ji W; Che J; Kim AY; Yu T; Wen K; Anderson KC; Marto JA; Westover KD; Zhang T; Gray NS
J Med Chem; 2023 Mar; 66(5):3356-3371. PubMed ID: 36826833
[TBL] [Abstract][Full Text] [Related]
16. p21-Activated kinase inhibitors: a patent review.
Crawford JJ; Hoeflich KP; Rudolph J
Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
[TBL] [Abstract][Full Text] [Related]
17. A novel retro-inverso peptide is a preferential JNK substrate-competitive inhibitor.
Ngoei KR; Catimel B; Milech N; Watt PM; Bogoyevitch MA
Int J Biochem Cell Biol; 2013 Aug; 45(8):1939-50. PubMed ID: 23792175
[TBL] [Abstract][Full Text] [Related]
18. Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage.
Waetzig V; Herdegen T
Trends Pharmacol Sci; 2005 Sep; 26(9):455-61. PubMed ID: 16054242
[TBL] [Abstract][Full Text] [Related]
19. JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases.
Kumar A; Singh UK; Kini SG; Garg V; Agrawal S; Tomar PK; Pathak P; Chaudhary A; Gupta P; Malik A
Future Med Chem; 2015; 7(15):2065-86. PubMed ID: 26505831
[TBL] [Abstract][Full Text] [Related]
20. Tropomyosin receptor kinase inhibitors: a patent update 2009 - 2013.
McCarthy C; Walker E
Expert Opin Ther Pat; 2014 Jul; 24(7):731-44. PubMed ID: 24809946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
